
    
      All participants received 1 intramuscular dose of Fluzone Quadrivalent vaccine at the first
      visit.

      Immunogenicity and safety were assessed in all participants. Adverse events (AE) defined in
      EMA NfG CPMP/BWP/214/96 were collected for 3 days after vaccination, solicited AE pre-listed
      in the diary card were collected for 7 days after vaccination, unsolicited AEs were collected
      for 21 days after vaccination, and serious adverse event (SAE) information was collected
      throughout the study.
    
  